Shots:
- Tiziana identified new immune biomarkers in na-SPMS patients treated with nasal foralumab, using single-cell RNA sequencing of peripheral blood samples taken before treatment & at 3 as well as 6mos. post-administration
- Study showed that after dosing in ongoing ISPPEA (expanded access program; n=10), gene expression changed starting 3mos. incl. modulation of FoxP3 Tregs, CD4+/CD8+ central memory T cells, CD14+/- monocytes, & naïve B cells. This was linked to a decrease in microglial brain inflammation, measured by PET scans in patients
- Foralumab is a fully human anti-CD3 mAb that stimulates T cells after intranasal administration & is under assessment in P-IIa trial in na-SPMS patients
Ref: Tiziana Life Sciences | Image: Tiziana Life Sciences
Related News:- Silexion Therapeutics Reports Preclinical Data for SIL-204 in Combination with 1L Chemotherapies for Pancreatic Cancer
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
